TGF-beta1 on osteoimmunology and the bone component cells

Cell and Bioscience

Volumn 3, Issue 1, 2013, Pages

  Kasagi, Shimpei ^a   Chen, Wanjun ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873418009     PISSN: None     EISSN: 20453701     Source Type: Journal    
DOI: 10.1186/2045-3701-3-4     Document Type: Review

References (80)

1. Rho J, Takami M, Choi Y. Osteoimmunology: interactions of the immune and skeletal systems. Mol Cells 2004, 17(1):1-9.
2. McKarns SC, Schwartz RH. Distinct effects of TGF-beta 1 on CD4+ and CD8+ T cell survival, division, and IL-2 production: a role for T cell intrinsic Smad3. J Immunol 2005, 174(4):2071-2083.
3. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992, 359(6397):693-699. 10.1038/359693a0, 1436033.
4. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, Roberts AB, Sporn MB, Ward JM, Karlsson S. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A 1993, 90(2):770-774. 10.1073/pnas.90.2.770, 45747, 8421714.
5. Carreno BM, Collins M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol 2002, 20:29-53. 10.1146/annurev.immunol.20.091101.091806, 11861596.
6. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003, 198(12):1875-1886. 10.1084/jem.20030152, 2194145, 14676299.
7. Bellone G, Aste-Amezaga M, Trinchieri G, Rodeck U. Regulation of NK cell functions by TGF-beta 1. J Immunol 1995, 155(3):1066-1073.
8. Lee WC, Zhong C, Qian S, Wan Y, Gauldie J, Mi Z, Robbins PD, Thomson AW, Lu L. Phenotype, function, and in vivo migration and survival of allogeneic dendritic cell progenitors genetically engineered to express TGF-beta. Transplantation 1998, 66(12):1810-1817. 10.1097/00007890-199812270-00040, 9884280.
9. Wahl SM, McCartney-Francis N, Allen JB, Dougherty EB, Dougherty SF. Macrophage production of TGF-beta and regulation by TGF-beta. Ann N Y Acad Sci 1990, 593:188-196. 10.1111/j.1749-6632.1990.tb16111.x, 1695824.
10. Broide DH, Wasserman SI, Alvaro-Gracia J, Zvaifler NJ, Firestein GS. Transforming growth factor-beta 1 selectively inhibits IL-3-dependent mast cell proliferation without affecting mast cell function or differentiation. J Immunol 1989, 143(5):1591-1597.
11. Hayashi S, Gimble JM, Henley A, Ellingsworth LR, Kincade PW. Differential effects of TGF-beta 1 on lymphohemopoiesis in long-term bone marrow cultures. Blood 1989, 74(5):1711-1717.
12. Lomri A, Marie PJ. Bone cell responsiveness to transforming growth factor beta, parathyroid hormone, and prostaglandin E2 in normal and postmenopausal osteoporotic women. J Bone Miner Res 1990, 5(11):1149-1155.
13. Janssens K, Gershoni-Baruch R, Guanabens N, Migone N, Ralston S, Bonduelle M, Lissens W, Van Maldergem L, Vanhoenacker F, Verbruggen L, et al. Mutations in the gene encoding the latency-associated peptide of TGF-beta 1 cause Camurati-Engelmann disease. Nat Genet 2000, 26(3):273-275. 10.1038/81563, 11062463.
14. Rosen DM, Stempien SA, Thompson AY, Seyedin SM. Transforming growth factor-beta modulates the expression of osteoblast and chondroblast phenotypes in vitro. J Cell Physiol 1988, 134(3):337-346. 10.1002/jcp.1041340304, 3162457.
15. Seyedin SM, Thomas TC, Thompson AY, Rosen DM, Piez KA. Purification and characterization of two cartilage-inducing factors from bovine demineralized bone. Proc Natl Acad Sci U S A 1985, 82(8):2267-2271. 10.1073/pnas.82.8.2267, 397538, 3857579.
16. Thompson NL, Flanders KC, Smith JM, Ellingsworth LR, Roberts AB, Sporn MB. Expression of transforming growth factor-beta 1 in specific cells and tissues of adult and neonatal mice. J Cell Biol 1989, 108(2):661-669. 10.1083/jcb.108.2.661, 2115426, 2645303.
17. Kassem M, Kveiborg M, Eriksen EF. Production and action of transforming growth factor-beta in human osteoblast cultures: dependence on cell differentiation and modulation by calcitriol. Eur J Clin Invest 2000, 30(5):429-437. 10.1046/j.1365-2362.2000.00645.x, 10809903.
18. Jilka RL, Weinstein RS, Bellido T, Parfitt AM, Manolagas SC. Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J Bone Miner Res 1998, 13(5):793-802. 10.1359/jbmr.1998.13.5.793, 9610743.
19. Lucas PA. Chemotactic response of osteoblast-like cells to transforming growth factor beta. Bone 1989, 10(6):459-463. 10.1016/8756-3282(89)90079-3, 2624828.
20. Maeda S, Dean DD, Gomez R, Schwartz Z, Boyan BD. The first stage of transforming growth factor beta1 activation is release of the large latent complex from the extracellular matrix of growth plate chondrocytes by matrix vesicle stromelysin-1 (MMP-3). Calcif Tissue Int 2002, 70(1):54-65. 10.1007/s002230010032, 11907708.
21. D'Ippolito G, Schiller PC, Ricordi C, Roos BA, Howard GA. Age-related osteogenic potential of mesenchymal stromal stem cells from human vertebral bone marrow. J Bone Miner Res 1999, 14(7):1115-1122. 10.1359/jbmr.1999.14.7.1115, 10404011.
22. Alliston T, Choy L, Ducy P, Karsenty G, Derynck R. TGF-beta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. EMBO J 2001, 20(9):2254-2272. 10.1093/emboj/20.9.2254, 125448, 11331591.
23. Maeda S, Hayashi M, Komiya S, Imamura T, Miyazono K. Endogenous TGF-beta signaling suppresses maturation of osteoblastic mesenchymal cells. EMBO J 2004, 23(3):552-563. 10.1038/sj.emboj.7600067, 1271802, 14749725.
24. Centrella M, Casinghino S, Kim J, Pham T, Rosen V, Wozney J, McCarthy TL. Independent changes in type I and type II receptors for transforming growth factor beta induced by bone morphogenetic protein 2 parallel expression of the osteoblast phenotype. Mol Cell Biol 1995, 15(6):3273-3281. 230560, 7760823.
25. Canalis E, Economides AN, Gazzerro E. Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev 2003, 24(2):218-235. 10.1210/er.2002-0023, 12700180.
26. Zhou S. TGF-beta regulates beta-catenin signaling and osteoblast differentiation in human mesenchymal stem cells. J Cell Biochem 2011, 112(6):1651-1660. 10.1002/jcb.23079, 3079785, 21344492.
27. Spinella-Jaegle S, Roman-Roman S, Faucheu C, Dunn FW, Kawai S, Gallea S, Stiot V, Blanchet AM, Courtois B, Baron R, et al. Opposite effects of bone morphogenetic protein-2 and transforming growth factor-beta1 on osteoblast differentiation. Bone 2001, 29(4):323-330. 10.1016/S8756-3282(01)00580-4, 11595614.
28. Komori T. Regulation of bone development and maintenance by Runx2. Frontiers in bioscience: a journal and virtual library 2008, 13:898-903.
29. Hattersley G, Chambers TJ. Effects of transforming growth factor beta 1 on the regulation of osteoclastic development and function. J Bone Miner Res 1991, 6(2):165-172.
30. Murakami T, Yamamoto M, Ono K, Nishikawa M, Nagata N, Motoyoshi K, Akatsu T. Transforming growth factor-beta1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells. Biochem Biophys Res Commun 1998, 252(3):747-752. 10.1006/bbrc.1998.9723, 9837778.
31. Pilkington MF, Sims SM, Dixon SJ. Transforming growth factor-beta induces osteoclast ruffling and chemotaxis: potential role in osteoclast recruitment. J Bone Miner Res 2001, 16(7):1237-1247. 10.1359/jbmr.2001.16.7.1237, 11450699.
32. Karst M, Gorny G, Galvin RJ, Oursler MJ. Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-beta regulation of osteoclast differentiation. J Cell Physiol 2004, 200(1):99-106. 10.1002/jcp.20036, 15137062.
33. Dieudonne SC, Foo P, van Zoelen EJ, Burger EH. Inhibiting and stimulating effects of TGF-beta 1 on osteoclastic bone resorption in fetal mouse bone organ cultures. J Bone Miner Res 1991, 6(5):479-487.
34. Takai H, Kanematsu M, Yano K, Tsuda E, Higashio K, Ikeda K, Watanabe K, Yamada Y. Transforming growth factor-beta stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells. J Biol Chem 1998, 273(42):27091-27096. 10.1074/jbc.273.42.27091, 9765225.
35. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89(2):309-319. 10.1016/S0092-8674(00)80209-3, 9108485.
36. Seshasayee D, Wang H, Lee WP, Gribling P, Ross J, Van Bruggen N, Carano R, Grewal IS. A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response. J Biol Chem 2004, 279(29):30202-30209. 10.1074/jbc.M403968200, 15145935.
37. Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 2004, 15(6):457-475. 10.1016/j.cytogfr.2004.06.004, 15561602.
38. D'Amelio P, Isaia G, Isaia GC. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. J Endocrinol Invest 2009, 32(4 Suppl):6-9.
39. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284(5411):143-147. 10.1126/science.284.5411.143, 10102814.
40. Cashman JD, Eaves AC, Raines EW, Ross R, Eaves CJ. Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures. I. Stimulatory role of a variety of mesenchymal cell activators and inhibitory role of TGF-beta. Blood 1990, 75(1):96-101.
41. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002, 418(6893):41-49. 10.1038/nature00870, 12077603.
42. Jorgensen C, Djouad F, Apparailly F, Noel D. Engineering mesenchymal stem cells for immunotherapy. Gene Ther 2003, 10(10):928-931. 10.1038/sj.gt.3302019, 12732877.
43. Kang JW, Kang KS, Koo HC, Park JR, Choi EW, Park YH. Soluble factors-mediated immunomodulatory effects of canine adipose tissue-derived mesenchymal stem cells. Stem Cells Dev 2008, 17(4):681-693. 10.1089/scd.2007.0153, 18717642.
44. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S, Gianni AM. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99(10):3838-3843. 10.1182/blood.V99.10.3838, 11986244.
45. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999, 189(9):1363-1372. 10.1084/jem.189.9.1363, 2193062, 10224276.
46. Chen W. IDO: more than an enzyme. Nat Immunol 2011, 12(9):809-811. 10.1038/ni.2088, 21852775.
47. Rappaport RS, Dodge GR. Prostaglandin E inhibits the production of human interleukin 2. J Exp Med 1982, 155(3):943-948. 10.1084/jem.155.3.943, 2186623, 6977613.
48. Park MJ, Park HS, Cho ML, Oh HJ, Cho YG, Min SY, Chung BH, Lee JW, Kim HY, Cho SG. Transforming growth factor beta-transduced mesenchymal stem cells ameliorate experimental autoimmune arthritis through reciprocal regulation of Treg/Th17 cells and osteoclastogenesis. Arthritis Rheum 2011, 63(6):1668-1680. 10.1002/art.30326, 21384335.
49. Massa G, Wyllie JP, Pratt AM, Molineux G, Schofield R. Marrow repopulation in mice treated with busulphan or isopropyl methane sulphonate and bone marrow. Br J Haematol 1987, 66(1):11-14.
50. Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol 2012, 12(5):383-396. 10.1038/nri3209, 22531326.
51. Wilson A, Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol 2006, 6(2):93-106. 10.1038/nri1779, 16491134.
52. Yamazaki S, Ema H, Karlsson G, Yamaguchi T, Miyoshi H, Shioda S, Taketo MM, Karlsson S, Iwama A, Nakauchi H. Nonmyelinating Schwann cells maintain hematopoietic stem cell hibernation in the bone marrow niche. Cell 2011, 147(5):1146-1158. 10.1016/j.cell.2011.09.053, 22118468.
53. Gao Y, Qian WP, Dark K, Toraldo G, Lin AS, Guldberg RE, Flavell RA, Weitzmann MN, Pacifici R. Estrogen prevents bone loss through transforming growth factor beta signaling in T cells. Proc Natl Acad Sci U S A 2004, 101(47):16618-16623. 10.1073/pnas.0404888101, 534514, 15531637.
54. Joyce ME, Roberts AB, Sporn MB, Bolander ME. Transforming growth factor-beta and the initiation of chondrogenesis and osteogenesis in the rat femur. J Cell Biol 1990, 110(6):2195-2207. 10.1083/jcb.110.6.2195, 2116133, 2351696.
55. Hill PA, Tumber A, Meikle MC. Multiple extracellular signals promote osteoblast survival and apoptosis. Endocrinology 1997, 138(9):3849-3858. 10.1210/en.138.9.3849, 9275074.
56. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000, 191(2):275-286. 10.1084/jem.191.2.275, 2195746, 10637272.
57. Chua CC, Chua BH, Chen Z, Landy C, Hamdy RC. TGF-beta1 inhibits multiple caspases induced by TNF-alpha in murine osteoblastic MC3T3-E1 cells. Biochim Biophys Acta 2002, 1593(1):1-8. 10.1016/S0167-4889(02)00257-4, 12431778.
58. Oldfield V, Plosker GL. Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. BioDrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy 2009, 23(2):125-135.
59. Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med 2007, 204(1):33-39. 10.1084/jem.20061531, 2118431, 17200409.
60. Steiner G, Tohidast-Akrad M, Witzmann G, Vesely M, Studnicka-Benke A, Gal A, Kunaver M, Zenz P, Smolen JS. Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology (Oxford) 1999, 38(3):202-213.
61. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999, 103(9):1345-1352. 10.1172/JCI5703, 408356, 10225978.
62. Zhou L, Lopes JE, Chong MM, Ivanov II, Min R, Victora GD, Shen Y, Du J, Rubtsov YP, Rudensky AY, et al. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 2008, 453(7192):236-240. 10.1038/nature06878, 2597437, 18368049.
63. Goldberg M, Nadiv O, Luknar-Gabor N, Agar G, Beer Y, Katz Y. Synergism between tumor necrosis factor alpha and interleukin-17 to induce IL-23 p19 expression in fibroblast-like synoviocytes. Mol Immunol 2009, 46(8-9):1854-1859.
64. Notley CA, Inglis JJ, Alzabin S, McCann FE, McNamee KE, Williams RO. Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J Exp Med 2008, 205(11):2491-2497. 10.1084/jem.20072707, 2571924, 18936235.
65. Husby G, Williams RC. Immunohistochemical studies of interleukin-2 and gamma-interferon in rheumatoid arthritis. Arthritis Rheum 1985, 28(2):174-181. 10.1002/art.1780280212, 3918543.
66. Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 2000, 408(6812):600-605. 10.1038/35046102, 11117749.
67. Liu Y, Wang L, Kikuiri T, Akiyama K, Chen C, Xu X, Yang R, Chen W, Wang S, Shi S. Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-gamma and TNF-alpha. Nat Med 2011, 17(12):1594-1601. 10.1038/nm.2542, 3233650, 22101767.
68. Zaiss MM, Sarter K, Hess A, Engelke K, Bohm C, Nimmerjahn F, Voll R, Schett G, David JP. Increased bone density and resistance to ovariectomy-induced bone loss in FoxP3-transgenic mice based on impaired osteoclast differentiation. Arthritis Rheum 2010, 62(8):2328-2338. 10.1002/art.27535, 20506516.
69. Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med 1996, 2(10):1132-1136. 10.1038/nm1096-1132, 8837613.
70. Matsuda T, Yamamoto T, Muraguchi A, Saatcioglu F. Cross-talk between transforming growth factor-beta and estrogen receptor signaling through Smad3. J Biol Chem 2001, 276(46):42908-42914. 10.1074/jbc.M105316200, 11555647.
71. Ash P, Loutit JF, Townsend KM. Osteoclasts derived from haematopoietic stem cells. Nature 1980, 283(5748):669-670. 10.1038/283669a0, 7354855.
72. Centrella M, McCarthy TL, Canalis E. Glucocorticoid regulation of transforming growth factor beta 1 activity and binding in osteoblast-enriched cultures from fetal rat bone. Mol Cell Biol 1991, 11(9):4490-4496. 361319, 1875934.
73. Qin L, Raggatt LJ, Partridge NC. Parathyroid hormone: a double-edged sword for bone metabolism. Trends Endocrinol Metab 2004, 15(2):60-65. 10.1016/j.tem.2004.01.006, 15036251.
74. Keen RW, Spector TD. Role and evolution of therapeutic options. Osteoporos Int 1996, 6(Suppl 2):16-20.
75. Skjodt H, Gallagher JA, Beresford JN, Couch M, Poser JW, Russell RG. Vitamin D metabolites regulate osteocalcin synthesis and proliferation of human bone cells in vitro. J Endocrinol 1985, 105(3):391-396. 10.1677/joe.0.1050391, 3873510.
76. Galli M, Caniggia M. Osteocalcin. Minerva Med 1984, 75(42):2489-2501.
77. Subramaniam N, Leong GM, Cock TA, Flanagan JL, Fong C, Eisman JA, Kouzmenko AP. Cross-talk between 1,25-dihydroxyvitamin D3 and transforming growth factor-beta signaling requires binding of VDR and Smad3 proteins to their cognate DNA recognition elements. J Biol Chem 2001, 276(19):15741-15746. 10.1074/jbc.M011033200, 11278818.
78. Banerjee C, Stein JL, Van Wijnen AJ, Frenkel B, Lian JB, Stein GS. Transforming growth factor-beta 1 responsiveness of the rat osteocalcin gene is mediated by an activator protein-1 binding site. Endocrinology 1996, 137(5):1991-2000. 10.1210/en.137.5.1991, 8612540.
79. Gurlek A, Kumar R. Regulation of osteoblast growth by interactions between transforming growth factor-beta and 1alpha,25-dihydroxyvitamin D3. Crit Rev Eukaryot Gene Expr 2001, 11(4):299-317.
80. Staal A, Geertsma-Kleinekoort WM, Van Den Bemd GJ, Buurman CJ, Birkenhager JC, Pols HA, Van Leeuwen JP. Regulation of osteocalcin production and bone resorption by 1,25-dihydroxyvitamin D3 in mouse long bones: interaction with the bone-derived growth factors TGF-beta and IGF-I. J Bone Miner Res 1998, 13(1):36-43. 10.1359/jbmr.1998.13.1.36, 9443788.